REG - Diaceutics PLC - Cancellation of Share Premium Account

DiaceuticsAnnouncement

24/10/2024 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241024:nRSX5086Ja&default-theme=true

RNS Number : 5086J  Diaceutics PLC  24 October 2024

24 October 2024

 

Diaceutics plc

 

(the "Company")

 

Cancellation of Share Premium Account

 

 

Belfast and London, 24 October 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce that earlier today the High Court of Justice in Northern
Ireland confirmed the cancellation of the sum standing to the credit of the
Company's share premium account (the "Reduction of Capital"). The Reduction of
Capital will become effective on registration of the Court order at Companies
House, which is expected to occur in the next few days.

 

The Reduction of Capital, as described in the AGM Notice that was sent to
shareholders on 29 May 2024 and which is available on the Company's website
(https://investors.diaceutics.com), was approved by way of a special
resolution passed by the shareholders of the Company at the annual general
meeting held on 24 June 2024.

 

The purpose of the Reduction of Capital is to create distributable reserves
which will provide the Company with flexibility to support, amongst other
things, share buy-backs, the funding of the Company's share option schemes and
the payment of dividends or other distributions to shareholders in the future.

 

 

 

 Enquiries:

 Diaceutics PLC                                  Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Executive Officer           investorrelations@diaceutics.com
 Nick Roberts, Chief Financial Officer

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 Alma Strategic Communications                   Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon                  diaceutics@almastrategic.com

 

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKQBQDBDDAKB